Opal (Cullinan Therapeutics)

N/A

Report date: 2024/04/25 14:31:57

Base Information

Drug NameOpal (Cullinan Therapeutics)
Drug Alias NamePD-1 x CD137L fusion protein (Cullinan Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed cell death protein 1 blockersTumor necrosis factor receptor superfamily member 9 agonists
TargetsTumor necrosis factor receptor superfamily member 9Programmed cell death protein 1
Therapy Area/IndicationsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCullinan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCullinan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsColonic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A